billS4387Event Monday, April 27, 2026Analyzed

Protect Moms From Domestic Violence Act

Neutral
Impact1/10

Summary

S4387, the Protect Moms From Domestic Violence Act, is an early-stage bill introduced in the Senate and referred to committee. It contains no authorized funding, no specific mandates on private sector entities, and no market-moving mechanisms. No actionable market impact exists at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S4387 is in the earliest legislative stage—introduced and referred to committee.
  • 2.No funding amount, no mandates, and no private sector obligations are specified.
  • 3.No market impact is identifiable from the available data.

Market Implications

There are no market implications from this bill at this time. No tickers are affected. Investors should monitor committee activity and any subsequent amendments that introduce specific funding or regulatory mechanisms.

Full Analysis

On April 27, 2026, Senator Shaheen (D-NH) introduced S4387, the Protect Moms From Domestic Violence Act. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. It has one cosponsor and two total actions, both on the same day. This is an early-stage procedural action with no committee markup, no hearings scheduled, and no companion bill in the House. The bill's title suggests a focus on maternal health and domestic violence prevention, but no actual bill text or funding authorization is provided in the available data. Without specific policy mechanisms—such as grant programs, tax credits, regulatory mandates, or procurement requirements—there is no identifiable money trail for private sector companies. The legislative path requires committee consideration, potential amendments, a Senate floor vote, House passage, and presidential action. Given the early stage and lack of detail, there is zero near-term market impact. No publicly traded companies are directly affected by this procedural referral.

Market Impact Score

1/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.